You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中金:料美倡新冠疫苗专利豁免存不确定性、量产壁垒高 料对内地厂商影响有限
格隆汇 05-10 11:43

中金发表报告表示,印度已连续多日报道多例新增新冠病例,该行认为海外疫情仍面临蔓延的压力,上周受美国总统拜登宣布新冠疫苗专利的豁免影响,新冠疫苗相关企业出现一定程度的回调。

该行认为,上述政策的落地和实施,仍需美国和其他国家以及WTO的逐步协商,存在一定不确定性;同时,相关疫苗大规模生产工艺存在较高壁垒,需要较长时间的摸索,原材料仍较为紧缺。因此,该行认为该政策对国内主要新冠疫苗厂商影响有限,仍可持续关注新冠疫苗持续接种放量带来的投资机会。

中金指,伴随上市公司年报、首季报披露完毕,市场进入业绩真空期,缺乏股价推动因素,该行认为在目前估值仍然不低的背景下,存在一定的下行风险。但从中长期看,创新、消费、国际化仍将是优质企业发展的方向,该行建议在估值回落时加强配置,享受企业长期的成长空间。短期由于市场流动性及情绪仍处于高位,各类热点层出不穷,建议投资者谨慎对待。

该行指旗下海外医药股的投资组合,包括药明生物(2269.HK)、阿里健康(0241.HK)、信达生物(1801.HK)、康方生物(9926.HK)、启明医疗(2500.HK)、海吉亚医疗(6078.HK)及威高股份(1066.HK)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account